DrugPatentWatch Database Preview
Email this page to a colleague» See Plans and Pricing
« Back to Dashboard
MLN1117 is an investigational drug.
There have been 8 clinical trials for MLN1117. The most recent clinical trial was a Phase 1 trial, which was initiated on June 1st 2016.
The most common disease conditions in clinical trials are Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, and Neoplasms. The leading clinical trial sponsors are Millennium Pharmaceuticals, Inc., European Network of Translational Research in Ovarian Cancer - EUTROC, and European Network of Individualized Treatment in Endometrial Cancer - ENITEC.
There are four US patents protecting this investigational drug and sixty-five international patents.
Recent Clinical Trials for MLN1117
|Evaluation of the Safety and Tolerability of TAK-228 With TAK-117 and Paclitaxel in Advanced Solid Tumors||Avera McKennan Hospital & University Health Center||Phase 1|
|MLN0128 and MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adults With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma||Millennium Pharmaceuticals, Inc.||Phase 2|
|Phase 2 Study of MLN0128, Combination of MLN0128 With MLN1117, Paclitaxel and Combination of MLN0128 With Paclitaxel in Women With Endometrial Cancer||European Network of Individualized Treatment in Endometrial Cancer - ENITEC||Phase 2|
Top disease conditions for MLN1117
Top clinical trial sponsors for MLN1117
|Drugname||Patent Number||Patent Title||Patent Assignee||Estimated Expiration|
|MLN1117||Start Trial||Heterocyclic compounds and uses thereof||INTELLIKINE, INC. (La Jolla, CA)||Start Trial|
|MLN1117||Start Trial||Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof||Intellikine LLC (La Jolla, CA)||Start Trial|
|MLN1117||Start Trial||Kinase inhibitor polymorphs||Intellikine LLC (La Jolla, CA) Sigma-Aldrich Company Limited (GB)||Start Trial|
|MLN1117||Start Trial||Combination of kinase inhibitors and uses thereof||Intellikine LLC (La Jolla, CA)||Start Trial|
|>Drugname||>Patent Number||>Patent Title||>Patent Assignee||>Estimated Expiration|
|Drugname||Country||Document Number||Estimated Expiration||Related US Patent|
|>Drugname||>Country||>Document Number||>Estimated Expiration||>Related US Patent|